104 results about "Fibronectins" patented technology

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

The invention discloses a recombinant fibronectin fusion protein and application thereof. The recombinant fibronectin fusion protein comprises a recombinant fibronectin mutant (FN1) and a platelet factor 4 (PF4), the amino acid sequence of the recombinant fibronectin is as shown in SEQ ID NO. 3 or SEQ ID NO. 4. The molecular weight of the recombinant fibronectin fusion protein is less than 90KDa, and the recombinant fibronectin fusion protein is good in solubility, simple in preparation process and convenient to purify; the recombinant fibronectin provided by the invention has novel recombinant fibronectin, and can inhibit inflammation in a wound healing process, so that mouse skin injury healing is efficiently promoted, and a new thought can be provided for development of wound healing drugs. In addition, when the platelet factor 4 is creatively fused to the N end of the fibronectin mutant, the cell proliferation activity can be obviously and effectively promoted.

The invention discloses a double-structural-domain recombinant human fibronectin, the sequence of which is shown as SEQ ID NO.3, and the double-structural-domain recombinant human fibronectin is formed by fusing a collagen binding structural domain and a cell binding structural domain of human fibronectin. The invention also provides a recombinant expression vector containing the protein coding gene and a host cell. The protein is efficiently expressed through eukaryotic cells and engineering bacteria escherichia coli, and a fermentation and purification process suitable for an industrial scale is established in a matched manner. Functional experiments prove that compared with commercially available fibronectin products with a single structural domain, the double-structural domain recombinant human chemical fibronectin disclosed by the invention can remarkably promote proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, skincare and biomedical materials.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

To provide polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, and further to provide methods of making and using the same.SOLUTION: Provided are: polypeptides including specific sequences or an amino acid sequence that is at least 90% identical to an amino acid sequence of any combination thereof; or a polypeptide including specific sequences or an amino acid sequence of any combination thereof. In some embodiments, an FN3 domain does not naturally exist. In some embodiments, the FN3 domain binds to human CD71 at a site on CD71 that does not compete with transferrin binding to CD71.SELECTED DRAWING: None

The invention belongs to the technical field of recombinant proteins, particularly discloses recombinant human fibronectin, a preparation method and application of the recombinant human fibronectin in cosmetics, and aims to solve the technical problems that existing recombinant fibronectin is small in expression quantity and relatively low in activity. The recombinant human fibronectin disclosed by the invention is recombined after an active region of natural fibronectin is intercepted, the recombinant human fibronectin is introduced into a vector after codon optimization, escherichia coli is used as an expression host cell, and the recombinant human fibronectin disclosed by the invention is obtained after fermentation and purification. The recombinant human fibronectin disclosed by the invention is high in expression quantity and relatively good in biological activity, can promote cell adhesion, proliferation or migration, and has a wide application prospect in the field of cosmetics for skin care, beauty and the like.

The invention discloses beta-glucan medical beauty essence with a barrier repairing function, and belongs to the technical field of cosmetics. According to the invention, the fibronectin is wrapped with beta-glucan, then the fibronectin is secondarily wrapped with a thermosensitive film, and active ingredients are slowly released through hot compress, so that the transdermal amount is increased. Beta-glucan, fibronectin and callicarpa nudiflora extract are cooperated, triple anti-inflammatory repair is achieved, percutaneous water loss is reduced, and a long-term repair effect is achieved.

The invention belongs to the field of cosmetics, and discloses a ceramide E-containing polypeptide composition and application thereof. The polypeptide composition containing ceramide E is prepared from the following components in parts by mass: 5 to 10 parts of ceramide E, 3 to 6 parts of fibronectin, 3 to 6 parts of palmitoyl pentapeptide-4, 1.5 to 3.5 parts of ergothioneine, 20 to 40 parts of oil-phase solvent, 1.5 to 4.5 parts of caprylic / capric triglyceride, 0.5 to 2.5 parts of soybean lecithin, 0.5 to 1.5 parts of polysorbate-80, 0.1 to 0.5 part of cholesterol and the balance of water, wherein the total mass part of the water is 100. In the polypeptide composition disclosed by the invention, ceramide E, fibronectin, ergothioneine and palmitoyl pentapeptide-4 are mutually promoted and have synergistic interaction, and a final product shows very good repairing and antioxidant effects.

The invention discloses an antioxidant repairing composition and application thereof and cosmetics, the antioxidant repairing composition comprises the following components in parts by mass: 32-48 parts of a Chinese herbaceous peony extract combined factor, 8-12 parts of a radix sophorae flavescentis extract combined factor, 1.6-2.4 parts of zinc gluconate and 1.6-2.4 parts of a fibronectin factor, through the mutual cooperation of the four components, the antioxidant effect of the skin can be effectively improved, the damage of oxidative stress and inflammation to the skin can be effectively reduced, and the cell regeneration effect of the skin is promoted; belongs to the technical field of cosmetics.

The invention relates to a tightening and lifting mask and a preparation method thereof. The mask liquid comprises the following functional components: saccharomycetes / rice fermentation product filtrate, palmitoyl tripeptide-5 and fibronectin, the mass ratio of the saccharomycetes / rice fermentation product filtrate to the palmitoyl tripeptide-5 to the fibronectin is (0.1-30): (0.01-6): (0.01-2). Compared with the prior art, through the synergistic effects of the saccharomycetes / rice fermentation product filtrate, palmitoyl tripeptide-5 and fibronectin on the aspects of enhancing the skin barrier function, promoting collagen generation, slowing down collagen decomposition, regulating adhesion, migration and proliferation of cells, removing reactive oxygen free radicals and the like, collagen generation of the corium layer is promoted, and the skin care effect is achieved. Skin wrinkles are reduced, and a long-term tightening and lifting effect is achieved.

The invention discloses a long-acting heat-resistant stable recombinant human fibronectin and a preparation method thereof, relates to the technical field of recombinant proteins, and aims to solve the technical problem that existing recombinant fibronectin is easily hydrolyzed and inactivated in skin. According to the long-acting heat-resistant stable recombinant human chemical fibronectin, the amino acid sequence of the recombinant human chemical fibronectin is shown as SEQ ID No.3, the recombinant human chemical fibronectin is derived from natural fibronectin, and the recombinant human chemical fibronectin comprises a human chemical fibronectin binding region shown as SEQ ID No.1 and a four-segment repeated cell binding region shown as SEQ ID No.2.

The present invention relates to a composition comprising the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of fibrotic diseases. The composition according to the present invention inhibits the expression of collagen type 1 (COL1A1) or fibronectin and thus can be advantageously used as a composition for the prevention or treatment of fibrotic diseases.

The utility model discloses a fibronectin purification device which comprises a sterile box, a filter box and a plurality of filter assemblies, and the filter box is arranged in the sterile box; the multiple filter assemblies are arranged in the filter box, each filter assembly comprises a supporting box, a filter membrane, a sliding control frame, a control rod and two membrane pressing mechanisms, and the supporting box is arranged in the filter box; the filtering membrane is arranged on the supporting box; the sliding control frame is slidably arranged in the supporting box. One end of the control rod is connected with the sliding control frame, and the other end of the control rod extends out of the filter box; the two film pressing mechanisms are arranged on the two sides of the supporting box correspondingly. One end of the membrane pressing mechanism penetrates through the supporting box and abuts against the sliding control frame, and the other end of the membrane pressing mechanism abuts against the filtering membrane in a pressing mode. Therefore, the filter membrane is simple in mounting mode and convenient to operate, so that the mounting efficiency of the filter membrane is improved.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The present invention relates to a composition for preventing or treating liver fibrosis or liver fibrosis-associated diseases, comprising a USP10 inhibitor as an active ingredient. The composition comprising a USP10 inhibitor as an active ingredient, of the present invention, was confirmed to inhibit the activity and / or expression levels of collagen and fibronectin, which are associated with liver fibrosis. Thus, the composition can be used to enhance the effect of treating liver fibrosis and / or liver fibrosis-associated diseases.

The invention provides a fusion protein with high repair capacity, a preparation method and application thereof, and belongs to the technical field of hybrid peptides. The amino acid sequence of the fusion protein is shown as SEQ ID NO.1; the fusion protein is obtained by sequentially connecting the following modules in series: a functional domain 1 of fibronectin, a hydrophilic region 1 of elastin, a functional domain 1 of mussel mucin, a hydrophilic region 2 of elastin, a functional domain 2 of fibronectin, a hydrophilic region 3 of elastin, a functional domain 2 of mussel mucin, a hydrophilic region 4 of elastin and an integrin binding region of elastin. The fusion protein of fibronectin, elastin and mussel mucin is constructed, and the nucleotide sequence of the fusion protein is optimized, so that the relative migration rate of keratinocytes can be obviously improved, the expression quantity of repair-related genes of HaCat cells can be improved, the secretion quantity of skin stimulating factors can be reduced, and the inhibition rate on hyaluronidase can be improved; the skin repairing and relieving capability is improved.

The present invention discloses a recombinant human fibronectin with soothing composite function and its preparation method and application. The recombinant human fibronectin with soothing composite function has an amino acid sequence as shown in SEQ ID NO.1. The present invention adds the hyaluronic acid interaction segment of human fibronectin while retaining the main segment of human fibronectin cell adhesion and cell integrin receptor interaction, and connects the two domains with a flexible "linker" amino acid sequence GGS to form a recombinant human FN protein with composite function. In addition to the core characteristics of traditional recombinant fibronectin, the recombinant human fibronectin also has the function of soothing cell stimulation. The recombinant human fibronectin prepared by the present invention will have a good effect in soothing skin irritation in the field of functional active skin care products.

The invention provides a zirconium oxide surface functional modification method, and belongs to the technical field of biological materials. According to the method, an anti-fibronectin aptamer is used for modifying the surface of zirconium oxide so as to promote the formation of periimplant soft tissue attachment. According to the method, an anti-fibronectin aptamer is applied to zirconium oxide surface modification for the first time, the aptamer has high specificity and stability, and the aptamer serving as a molecular bridge can specifically recognize and combine with FN in the environment, so that directional enrichment and functionalization of the FN on the zirconium oxide surface are facilitated, and cell adhesion and soft tissue adhesion are promoted.

The current application describes various compositions and methods for the production of FN3-based binding proteins with improved stability properties. Aspects of the disclosure relate to polypeptides comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii or Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.

The present invention produces a large number of mesenchymal stem cells in a short time in a culture medium containing no heterologous components by including a step of culturing a cell population containing mesenchymal stem cells in the presence of a fibronectin fragment.

Mesothelin-binding fibronectin type III (Fn3) domain proteins having improved mesothelin binding characteristics are described.

Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) domain with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, methods of making thereof, and uses as therapeutic molecules for treatment and diagnosis of diseases and disorders.

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The invention relates to sesquiterpenoids Oxyphyllene F and Oxyphyllene G which are separated from fructus alpiniae oxyphyllae and application of the sesquiterpenoids Oxyphyllene G. Experimental research finds that the two compounds can inhibit the expression of fibronectin, type I collagen and alpha-smooth muscle actin in rat renal tubular duct epithelial cells induced by TGF-beta1, have anti-renal fibrosis activity, and can be used for preparing anti-renal fibrosis drugs. The fructus alpiniae oxyphyllae can be effectively used for preparing kidney protection drugs, the preparation method is good in reproducibility, the purity of the obtained compound is high, further pharmacological and clinical research on the compound is facilitated, the medicinal value of the fructus alpiniae oxyphyllae is expanded, and the economic and social benefits are huge.

The invention belongs to the technical field of biomedical treatment, and particularly relates to recombinant human fibronectin max-rhFN as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin mat-rhFN is as shown in SEQ ID NO. 2. The molecular weight of the recombinant human fibronectin mat-rhFN provided by the invention is about 130kDa, the purity is higher than 95%, and the endotoxin content is relatively low. Through cell biology detection, the recombinant human fibronectin mat-rhFN provided by the invention is good in activity, has the effects of promoting cell proliferation and cell adhesion, and also has a good protection effect in a keratinocyte anti-SDS stimulation test, and meanwhile, the recombinant human fibronectin mat-rhFN provided by the invention has a remarkable interaction with collagen.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

Mesothelin-binding fibronectin type III (Fn3) domain proteins having improved mesothelin binding characteristics are described.

The invention relates to the technical field of protein engineering, particularly discloses a human-like fibronectin and a skin filling composition thereof, and provides a recombinant human-like fibronectin, the amino acid sequence of which is as shown in SEQ ID No.1, and the recombinant human-like fibronectin can promote adhesion or migration of skin fibroblasts, so that the human-like fibronectin can be used as a skin filling composition. And the lasting stability of the molecular structure can be maintained in subcutaneous tissues. The skin filling composition containing the recombinant human-like fibronectin can provide supporting and filling functions through subcutaneous injection, so that the purpose of correcting wrinkles is achieved.